The recent development and clinical testing of PI3K/Akt/mTOR inhibitors have led to the conclusion that targeting the PI3K/Akt/mTOR pathway is a promising approach for the treatment of breast cancer [39]. This evidence concerns the gene AKT1 and breast cancer.